drugset / Trial / NCT01364181
The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 3
Completed
23 enrolled
Seoul National University Hospital
Dong-A PharmTech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.
Timeline
- Start
- 2010-03
- Primary completion
- 2011-03
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Udenafil | Small molecule | 50 mg | Oral |